Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Gulley on Checkpoint Inhibitors in Bladder Cancer

James L. Gulley, MD, PhD
Published: Monday, Mar 14, 2016



James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Checkpoint inhibitors are currently being investigated in a wide range of clinical trials in bladder cancer. Data has suggested significant activity of atezolizumab, pembrolizumab, avelumab in patients with metastatic bladder cancer.

Now that activity is being seen, further investigation is needed to determine if these agents should be used as single agents or in earlier settings, says Gulley.



James L. Gulley, MD, PhD, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, Director, Medical Oncology Service, CCR Office of the Clinical Director, National Cancer Institute, discusses checkpoint inhibitors in bladder cancer.

Checkpoint inhibitors are currently being investigated in a wide range of clinical trials in bladder cancer. Data has suggested significant activity of atezolizumab, pembrolizumab, avelumab in patients with metastatic bladder cancer.

Now that activity is being seen, further investigation is needed to determine if these agents should be used as single agents or in earlier settings, says Gulley.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x